HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Memorial Sloan Kettering Cancer Center · Tokyo National Hospital · +29 more institutions
Abstract
PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor ( EGFR)–mutated non–small-cell lung cancer (NSCLC). METHODS This phase II study (ClinicalTrials.gov identifier: NCT04619004 ) was designed to evaluate HER3-DXd in patients with advanced EGFR-mutated NSCLC previously treated with EGFR tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy (PBC). Patients received HER3-DXd 5.6 mg/kg…
Citation impact
- FWCI
- 52.51
- Percentile
- 100%
- References
- 27
Authors
29Topics & keywords
- Medicine
- Epidermal growth factor receptor
- Gefitinib
- Internal medicine
- Oncology
- Erlotinib
- Phases of clinical research
- Tyrosine kinase
- Good health and well-being
Funding
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- MSMemorial Sloan-Kettering Cancer Center
- ABArray BioPharma
- HHelsinn
- RPRegeneron Pharmaceuticals
- EExelixis
- TTTizona Therapeutics
- MTMirati Therapeutics
- BBeiGene
- IIncyte
- CBCalithera Biosciences
- TTTarveda Therapeutics
- SPSyndax Pharmaceuticals
- RTRibon Therapeutics
- YYuhan
- RMRevolution Medicines
- RTRelay Therapeutics
- SSeagen
- YTY-mAbs Therapeutics
- EEisai
- APAstellas Pharma
- OPOno Pharmaceutical
- GGenentech
- ESEMD Serono
- DSDaiichi Sankyo Europe